UCSF Brain Tumor Center Clinical Trials

This is a phase 1/2 clinical trial evaluating the safety, tolerability, and preliminary antitumor activity of TNG456 as monotherapy and in combination with abemaciclib in patients with solid tumors with methylthioadenosine phosphorylase (MTAP) loss. 

This phase 1 clinical trial studies how well the drug AZD1390 works in combination with radiation therapy to treat pediatric high-grade glioma, diffuse midline glioma, or diffuse intrinsic pontine glioma.

This phase 2 trial studies how well lower-dose radiation therapy after treatment with the chemotherapy drugs, carboplatin and etoposide, works against central nervous system (CNS) germinomas.

Studies have shown that patients with newly diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce t

Standard therapy for newly diagnosed average-risk or low-risk medulloblastoma includes surgery, radiation therapy, and treatment with chemotherapy medications like cisplatin.

This phase 1/2 trial is evaluating the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy to treat children and young adults with newly diagnosed high-grade gliomas (HGGs) that have alterations in the gene that encodes histone 3 (H3 K27-altered).